EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.

Adjuvant therapy with immune checkpoint inhibitors (ICIs) became standard for resected stage III/IV melanoma after the results from the CheckMate-238 and KEYNOTE-054 studies. However, 30% to 40% of patients relapse despite adjuvant therapy. 1 Weber J. Mandala M. Del Vecchio M. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017; 377: 1824-1835https://doi.org/10.1056/NEJMoa1709030 Crossref PubMed Scopus (1494) Google Scholar ,2 Eggermont A.M.M. Blank C.U. Mandala M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018; 378: 1789-1801https://doi.org/10.1056/NEJMoa1802357 Crossref PubMed Scopus (1171) Google Scholar